Improving the product development cycle for new therapies is a constant challenge for drug discovery researchers. Abeome’s DiSH™ technology enables the rapid detection and production of highly specific monoclonal antibodies.
Direct Selection of Hybrdomas (DiSH™) is a system in which mAb-secreting hybridoma cells co-express significant amounts of the membrane form of the secreted immunoglobulin (lg) on their surfaces. Subsequently, hybridomas with high affinity for the target antigen are labeled.
Once labelled, they can be isolated from among a pool of hundreds of thousands of cells in a matter of hours using fluorescence activated cell sorting (FACS) or magnetic separation. The total elapsed time from harvest to the first screening is typically 25 days, resulting in improved efficiency for detection of highly specific mAbs.